NCT00141726View on ClinicalTrials.gov

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

February 28, 2009

Conditions
Lung Injury, AcuteRespiratory Distress Syndrome, AdultBronchiolitis Obliterans
Interventions
DRUG

Etanercept

Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.

Trial Locations (1)

48109

The University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter